Background
Amylase is a digestive enzyme that normally acts extracellularly to cleave starch into smaller carbohydrate groups and, finally, into monosaccharides, by hydrolysis of internal alpha-1,4-glycoside bonds, which results in the production of maltose and oligosaccharides.
Among healthy individuals, the pancreas and the salivary glands account for almost all serum amylase, 40-45% from the pancreas and 55-60% from the salivary glands.
Serum amylase is increased in at least 75% of pancreatitis cases; however, serum amylase can be normal, even in the face of massive pancreatic necrosis. The major limitation of using serum amylase measurement in diagnosing pancreatitis is the lack of specificity.
Pathophysiology
Origins of serum amylase
A variety of organs and secretions contain amylase activity. The pancreas and salivary glands contain amylase concentrations that are several orders of magnitude greater than other organs. Electrophoresis shows that serum amylase is of 2 main types, as follows: (1) P-type amylase from the pancreas, and (2) S-type amylase from the salivary glands.
The other locations of amylase include fallopian tubes and cyst fluid, testes, lungs, thyroid, tonsils, breast milk, sweat, tears, and some malignant neoplasms. They contribute little to the serum amylase level. Fallopian tube secretions, tears, breast milk, and sweat have amylases with a similar electrophoretic mobility of salivary isoamylase. However, the salivary glands account for almost all of the S-type isoamylase.
Metabolic clearance of serum amylase
The exact mechanisms of serum amylase metabolism are still not fully understood. Humans who have had a nephrectomy or have renal insufficiency have average serum amylase levels 50% higher than healthy individuals. Therefore, the kidneys can be assumed to play a major role in amylase metabolism. However, the kidney is not the sole organ responsible for amylase clearance in humans. The extrarenal mechanisms of amylase clearance have not been clearly defined.
Because of the high serum amylase levels also observed in hepatic necrosis and cirrhosis, the liver is thought to play a role in amylase metabolism.
Factors influencing serum amylase
Many conditions have been reported to cause hyperamylasemia. Although hyperamylasemia is commonly assumed to be due to the release of amylase into the serum by the diseased organ, the precise relationship between hyperamylasemia and an affecting condition is not entirely clear. Hyperamylasemia is most commonly the result of (1) pancreatitis or parotitis, (2) decreased metabolic clearance of amylase, or (3) amylase released from an involved organ.
Causes
Pancreatic diseases
Acute or chronic pancreatitis is associated with increases in the P-type isoamylase. In acute pancreatitis, serum amylase is usually elevated 3-fold and then returns to normal by 3-7 days. Patients with pancreatitis associated with hypertriglyceridemia or those with considerable acinar cell injury due to previous episodes of pancreatitis or chronic pancreatitis may not exhibit hyperamylasemia.
Other reasons for hyperamylasemia that are associated with pancreatitis arepseudocysts, pancreatic ascites, pancreatic trauma,[1] and choledocholithiasis. Pancreatic trauma can be a result of blunt trauma, abdominal or retroperitoneal surgery, or endoscopic retrograde cannulation of pancreatic duct (ERCP). Trauma related to ERCP is thought to result from the regurgitation of amylase into the blood, which may occur in 75% of ERCPs, but most have no evidence of pancreatic injury. A 3- to 4-times increase in serum amylase levels 4 hours after ERCP predicts the occurrence of complicating postprocedure pancreatitis. In patients presenting with biliary-type abdominal pain, a 3-fold increase in serum amylase levels that returns to normal within 48-72 hours suggests stone passage through the common bile duct.
Salivary diseases
Parotitis is associated with increases in the S-type isoamylase. Parotitis is usually caused by trauma or surgery of the salivary gland, radiation to the neck area involving the parotid gland followed subsequently by duct obstruction, or calculi of the salivary duct.[2, 3, 4]
Another cause of damage to the salivary gland is from chronic alcoholism. Salivary amylase levels are 3 times higher than normal in 10% of patients with alcoholism; this may be related to chronic liver disease.
Decreased metabolic clearance
Renal failure results in increased S-type and P-type isoamylases.
Liver disease from hepatitis or cirrhosis also results in increased S-type and P-type isoamylases.
Macroamylasemia
Macroamylasemia is a benign condition in which the amylase molecule binds with a large complex molecule (eg, immunoglobulin, polysaccharide), thereby decreasing renal clearance and prolonging its half-life. About 2-5% of patients with hyperamylasemia have macroamylasemia.
Intestinal disease
Gut diseases, including mucosal inflammatory disease of the small intestine, mesenteric infarction, intestinal obstruction, appendicitis, and peritonitis, usually result in increased P-type isoamylase because of increased absorption of amylase from the intestinal lumen. Gut perforation leaks the contents into the peritoneum causing inflammation and absorption of amylase across the inflamed peritoneum. This can result in hyperamylasemia.
Female reproductive tract disease
Ruptured ectopic pregnancy, fallopian or ovarian cysts, and salpingitis can result in increased S-type isoamylase.
Miscellaneous causes
Ectopic amylase production by lung, ovary, pancreas, and colon malignancies; pheochromocytoma; thymoma; multiple myeloma (increased salivary amylase); and breast cancer (increased pancreatic amylase) are miscellaneous causes of hyperamylasemia.
Acidosis, which can be due to (1) ketoacidosis that results in increased S-type and P-type isoamylases or (2) nonketotic acidosis that results in increased S-type isoamylase, can cause hyperamylasemia.
Amylase increases may occur postoperatively, resulting in increased S-type and P-type isoamylases; however, an increase in salivary amylase is more common. This may occur after extracorporeal circulation or nonabdominal surgery (eg, 30% of patients undergoing cardiac surgery have elevated S-type isoamylase).
Rare cases of hyperamylasemia have been reported in association with systemic lupus erythematosus (SLE), as well as with ciprofloxacin treatment. Other causes of hyperamylasemia include pneumonia (increased salivary amylase), cerebral trauma, burns, abdominal aortic aneurysms (increased pancreatic amylase), drugs (increased salivary and/or pancreatic amylase), anorexia nervosa and bulimia (increased salivary amylase), nonpathologic (increased salivary and/or pancreatic amylase), and organophosphate poisoning.[5, 6, 7]
Elevated pancreatic enzymes can be found in critically injured trauma patients even in the absence of true pancreatitis.[1] Reviewing data from 2,711 critically injured trauma patients who had not suffered pancreatic injury, Malinoski and colleagues found that 481 (18%) of these patients had elevated amylase levels (defined in the study as more than twice the upper limit of normal amylase levels). The investigators also found that, in comparison with patients without elevated serum amylase, a greater proportion of patients with elevated serum levels presented in shock (16% vs 8%), required massive transfusion (19% vs 9%), or developed organ failure (34% vs 16%). Their mortality rate was higher as well (23% vs 13%). Similarly, patients with elevated serum lipase also were more likely to need massive transfusion or to suffer organ failure.
The investigators could not determine whether the higher pancreatic enzyme levels reported in the study resulted from ischemia of the pancreas or from the translocation of intraluminal enteric pancreatic enzymes.
Lab Studies
The most widely used application of serum amylase measurements is to support a diagnosis of acute pancreatitis. In acute pancreatitis, the serum amylase is increased at least 3-fold in approximately 75% of cases on the initial day of symptoms; then, it usually returns to normal by 3-7 days. The specificity of the test increases with higher levels of the enzyme.
Serum amylase measurements are not very sensitive or specific for pancreatic injury because they may be normal in patients with preexisting acinar injury or chronic pancreatitis and because many other causes of hyperamylasemia are described (see Causes). One should remember that a patient with asymptomatic chronic hyperamylasemia almost never has pancreatic disease as the cause of the amylase elevation.[8, 8] Serum isoamylase measurements to determine S-type isoamylase, P-type isoamylase, or macroamylasemia are the best tests to use when the etiology of hyperamylasemia is obscure.
An amylase level obtained within a few hours after an endoscopic retrograde cholangiopancreatogram has value in predicting postprocedure pancreatitis. In one study, a 6-hour level of greater than 5 times normal had a predictive accuracy of 86%.[9]
In patients undergoing pancreatoduodenectomy, a postoperative day 0 serum amylase level of less than 130 IU/l is reported to allow for the early and accurate categorization of patients at least risk for clinically significant postoperative pancreatic fistula. This may help identify patients suitable for an early removal of drains placed at the time of surgery.[10]
Measuring the salivary amylase level could be useful for stress assessment and is a marker for sympathetic activity.[11] It has been used in assessing stress levels of space crew members and populations working in a stressful and isolated environment.[12]
The amylase-to-creatinine clearance ratio (ACR) can help differentiate acute pancreatitis from other conditions[22] . This ratio is calculated using the following equation:
- ACR = (amylase [urine] X creatinine [serum])/(amylase [serum] X creatinine [urine]) X 100
An ACR of greater than 5% suggests acute pancreatitis. However, the ACR is also known to be increased in diabetic ketoacidosis and renal disease and after surgery. An ACR of less than 1% suggests macroamylasemia. Because findings of urinary amylase are relatively nonspecific, calculations for urinary amylase excretion have almost no clinical value. Generally, the ACR measurement has been abandoned, except to confirm a diagnosis of macroamylasemia, which is characterized by a low ACR.
A lipase-to-amylase ratio of greater than 2 may suggest alcoholic pancreatitis, but it is not a reliable predictor of alcoholic pancreatitis.[13]
Special Concerns
In pancreatitis with associated hypertriglyceridemia, serum amylase levels may be erroneously normal. This is attributed to an inhibitor associated with triglyceride elevations that interferes with the assay for the enzyme. Diluting the serum can reduce the activity of the inhibitor such that a recalculation of serum amylase can uncover true serum amylase levels.
References
- Malinoski DJ, Hadjizacharia P, Salim A, Kim H, Dolich MO, Cinat M, et al. Elevated serum pancreatic enzyme levels after hemorrhagic shock predict organ failure and death. J Trauma. 2009 Sep. 67(3):445-9.[Medline].
- Chen CC, Chen SY, Chen YS, Lo CY, Cheng PW. Mycobacterium fortuitum-induced persistent parotitis: successful therapy with clarithromycin and ciprofloxacin. Head Neck. 2007 Nov. 29(11):1061-4. [Medline].
- Gokel Y, Gulalp B, Acikalin A. Parotitis due to organophosphate intoxication. J Toxicol Clin Toxicol. 2002. 40(5):563-5. [Medline].
- Ericson S, Sjoback I. Salivary factors in children with recurrent parotitis. Part 2: Protein, albumin, amylase, IgA, lactoferrin lysozyme and kallikrein concentrations. Swed Dent J. 1996. 20(5):199-207. [Medline].
- Pata C, Akyuz U, Erzin Y, et al. Post-procedure elevated amylase and lipase levels after double-balloon enteroscopy: relations with the double-balloon technique. Dig Dis Sci. 2009 Sep 3. [Medline].
- Aktas H, Mensink PB, Haringsma J, et al. Low incidence of hyperamylasemia after proximal double-balloon enteroscopy: has the insertion technique improved?. Endoscopy. 2009 Aug. 41(8):670-3. [Medline].
- Zepeda-Gomez S, Barreto-Zuniga R, Ponce-de-Leon S,et al. Risk of hyperamylasemia and acute pancreatitis after double-balloon enteroscopy: a prospective study. Endoscopy. 2011 Sep. 43(9):766-70.[Medline].
- Dylewski ML, Prelack K, Keaney T, Sheridan RL. Asymptomatic hyperamylasemia and hyperlipasemia in pediatric patients with toxic epidermal necrolysis. J Burn Care Res. 2010 Mar-Apr. 31(2):292-6. [Medline].
- Kapetanos D, Kokozidis G, Kinigopoulou P, et al. The value of serum amylase and elastase measurements in the prediction of post-ERCP acute pancreatitis. Hepatogastroenterology. 2007 Mar. 54(74):556-60. [Medline].
- Palani Velu LK, Chandrabalan VV, et al. Serum amylase on the night of surgery predicts clinically significant pancreatic fistula after pancreaticoduodenectomy. HPB (Oxford). 2013 Nov 7. [Medline].
- Nater UM, Rohleder N. Salivary alpha-amylase as a non-invasive biomarker for the sympathetic nervous system: current state of research. Psychoneuroendocrinology. 2009 May. 34(4):486-96. [Medline].
- Rai B, Kaur J, Foing BH. Salivary amylase and stress during stressful environment: three Mars analog mission crews study. Neurosci Lett. 2012 Jun 14. 518(1):23-6. [Medline].
- Yilmaz UE, Yilmaz N, Titiz I, Basaranoglu M, Tarcin O. The utility of amylase and lipase as reliable predictive markers for functioning renal graft. Ann Transplant. 2012 Jul-Sep. 17(3):77-84. [Medline].
- Faro RS, Trafton HF, Organ CH Jr. Macroamylasemia. Surgery. 1977 Nov. 82(5):552-4. [Medline].
- Gallucci F, Buono R, Ferrara L, Madrid E, Miraglia S, Uomo G. Chronic asymptomatic hyperamylasemia unrelated to pancreatic diseases. Adv Med Sci. 2010 Dec 30. 55(2):143-5. [Medline].
- Gullo L. Chronic nonpathological hyperamylasemia of pancreatic origin. Gastroenterology. 1996 Jun. 110(6):1905-8. [Medline].
- Humphries LL, Adams LJ, Eckfeldt JH, Levitt MD, McClain CJ. Hyperamylasemia in patients with eating disorders. Ann Intern Med. 1987 Jan. 106(1):50-2. [Medline].
- Jensen DM, Royse VL, Bonello JN, Schaffner J. Use of amylase isoenzymes in laboratory evaluation of hyperamylasemia. Dig Dis Sci. 1987 Jun. 32(6):561-8. [Medline].
- Keim V, Teich N, Fiedler F, Hartig W, Thiele G, Mössner J. A comparison of lipase and amylase in the diagnosis of acute pancreatitis in patients with abdominal pain. Pancreas. 1998 Jan. 16(1):45-9. [Medline].
- Lee WC, Yang CC, Deng JF, Wu ML, Ger J, Lin HC, et al. The clinical significance of hyperamylasemia in organophosphate poisoning. J Toxicol Clin Toxicol. 1998. 36(7):673-81. [Medline].
- Levitt MD, Ellis C. A rapid and simple assay to determine if macroamylase is the cause of hyperamylasemia. Gastroenterology. 1982 Aug. 83(2):378-82. [Medline].
- MacGregor IL, Zakim D. A cause of hyperamylasemia associated with chronic liver disease.Gastroenterology. 1977 Mar. 72(3):519-23. [Medline].
- Marten A, Beales D, Elias E. Mechanism and specificity of increased amylase/creatinine clearance ratio in pancreatitis. Gut. 1977 Sep. 18(9):703-8. [Medline].
- Minakami H, Sato I, Gunj Y, Taniguchi Y. Idiopathic hyperamylasemia. Hepatogastroenterology. 1998 Jul-Aug. 45(22):1148-9. [Medline].
- Paajanen H, Nuutinen P, Harmoinen A, et al. Hyperamylasemia after cardiopulmonary bypass: pancreatic cellular injury or impaired renal excretion of amylase?. Surgery. 1998 May. 123(5):504-10. [Medline].
- Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go?.Gastroenterol Clin North Am. 1990 Dec. 19(4):793-810. [Medline].
- Quilez C, Martinez J, Gomez A, Trigo C, Palazon JM, Belda G, et al. [Chronic elevation of enzymes of pancreatic origin in asymptomatic patients]. Gastroenterol Hepatol. 1998 May. 21(5):209-11. [Medline].
- Vinicor F, Lehrner LM, Karn RC, Merritt AD. Hyperamylasemia in diabetic ketoacidosis: sources and significance. Ann Intern Med. 1979 Aug. 91(2):200-4. [Medline].
- Warshaw AL, Hawboldt MM. Puzzling persistent hyperamylasemia, probably neither pancreatic nor pathologic. Am J Surg. 1988 Mar. 155(3):453-6. [Medline].
- Weaver DW, Busuito MJ, Bouwman DL, Wilson RF. Interpretation of serum amylase levels in the critically ill patient. Crit Care Med. 1985 Jul. 13(7):532-3. [Medline].